Global Contraceptive Drugs and Devices Market - Segmented by Contraceptive Methods, Mode of Delivery, Type of Device, Gender, and Geography - Growth, Trends, and Forecasts (2017 - 2022)

The global market for contraceptives is estimated to be worth USD 6.05 billion in the year 2015. This market is expected to reach USD 8.78 billion by the end of 2020. During this period, the market is projected to grow at a CAGR of 7.8%.

Global Contraceptive Drugs and Devices Market- Market Dynamics

The report details several factors driving and restraining the market. Some of these are discussed below.


Contributing to the growth of the contraceptives market globally is the necessity to avoid unwanted pregnancies and their complications. A high percentage of women who are sexually active do not want to become pregnant. This number is as high as 70% in the USA. The need to avoid unwanted pregnancies, especially in teenage women, is one of the major drivers for this market.

It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. These are also some of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population. Government initiatives promoting the use of contraceptives to avoid unnecessary births and the health benefits from using the contraceptives have also been important players in the growth of the market.


Factors such as religious and cultural opposition in certain emerging nations have been restraining the growth of this market. Along with this, the fear of certain side effects and issues such as infertility resulting from the use of contraceptives have been major setbacks from the market point of view. Issues such as limited access to contraceptives in the developing and economically backward nations have been another setback in this market. It is estimated that among the global female population, the need for contraceptive prevalence or meeting the needs of family planning is estimated to as high as 16.2%.

The global market for contraceptive drugs and devices can be segmented on the basis of the type of contraceptive method, mode of delivery, device, gender, and geography. On the basis of the type of contraceptive method used, the market is segmented into pills, implants, sterilization, IUDs, injectable, male condoms, vaginal barrier methods, etc. On the basis of the mode of delivery, the market is segmented into oral, topical and contraceptive injectable. On the basis of the device, the market is segmented into condoms, diaphragms, cervical caps, sponges and vaginal rings.

Geographically, North America holds the largest market share. Over 90% of the female population in North America uses the modern contraceptive techniques. The use of contraceptives is the highest in North America, whose share is estimated to be 75.4%. Following North America, Europe is the second largest market globally. The contraceptive prevalence in Europe is estimated to be 70%. The emerging nations have shown an increase in contraceptive prevalence in recent times. However, there is a large population with unmet needs in terms of contraceptive usage. This makes emerging nations a hot destination for the contraceptives market.

Some of the key players in the market are:

Actavis PLC

ANI Pharmaceuticals, Inc.

Church & Dwight, Co. Inc.

Fuji Latex Co., Ltd.

Johnson & Johnson, Ltd.

Lupin Pharmaceuticals, Ltd.

Okamato Industries, Inc.


Reckitt Benckiser Group, PLC

What the Report Offers

Market definition for global contraceptive drugs & devices market along with identification of key drivers and restraints for the market.

Market analysis for the contraceptives drugs & devices market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

1. Introduction

1.1 Report Description

1.2 Research Methodology

2. Executive Summary

3. Market Overview

3.1 Market Drivers

3.1.1 Product Innovation

3.1.2 Increasing incidence of STD's

3.1.3 Pregnancy prevention

3.1.4 Immediate Health benefits other than birth control

3.1.5 Rise in Government initiatives to prevent unwanted abortions and pregnancies

3.1.6 Rapid increase in global population

3.2 Market Restraints

3.2.1 Fear or experience of side effects

3.2.2 Cultural or Religious opposition

3.2.3 Limited access to contraception

3.2.4 Infertility issues

3.2.5 Economic constraints

3.3 Market opportunities

3.4 Porter's Five Force Analysis

3.4.1 Threat of a new entrant

3.4.2 Internal Rivalry

3.4.3 Buyer Bargaining Power

3.4.4 Supplier Bargaining Power

3.4.5 Threat of substitutes

4. Market Segmentation- Global Market for Contraceptive Drugs and Devices

4.1 Segmentation by Contraceptive Method

4.1.1 Sterilization

4.1.2 Pills

4.1.3 Implants

4.1.4 Injectable

4.1.5 Intrauterine Device (IUD)

4.1.6 Male Condoms

4.1.7 Vaginal barrier methods

4.1.8 Others

4.2 Segmentation by Mode of Delivery

4.2.1 Oral Contraceptives Combined Oral Contraceptive Pills Progestin-only Pill Emergency Contraceptive pills

4.2.2 Topical Contraceptives

4.2.3 Contraceptive Injectable

4.3 Segmentation by type of device

4.3.1 Condoms

4.3.2 Diaphragms

4.3.3 Cervical Caps

4.3.4 Sponges

4.3.5 Vaginal Rings

4.3.6 IUD

4.3.7 Implants

4.4 Segmentation by Gender

4.4.1 Male

4.4.2 Female

4.5 Segmentation by Geography

4.5.1 North America USA Canada Mexico

4.5.2 Europe UK Germany France Spain Italy Others

4.5.3 Asia-Pacific China India Japan South Korea Australia Others

4.5.4 Rest of the World

5. Competitive Landscape

5.1 Mergers & Acquisitions

5.2 New Product Launches

5.3 Agreements, Collaborations & Partnerships

5.4 Recommendations for New market players

6. Company Profiles

6.1 Bayer Healthcare

6.2 Pfizer

6.3 Merck & Co.

6.4 Teva Pharmaceuticals, Ltd.

6.5 Agile Therapeutics

6.6 Actavis PLC

6.7 ANI Pharmaceuticals, Inc.

6.8 Church & Dwight, Co. Inc.

6.9 Fuji Latex Co., Ltd

6.10 Johnson & Johnson, Ltd

6.11 Lupin Pharmaceuticals, Ltd

6.12 Okamato Industries, Inc.

6.13 Reckitt Benckiser Group, PLC

6.14 The Female Health Company

6.15 Mylan Laboratories

7. Appendix

7.1 Abbreviations

7.2 Sources

7.3 Bibliography

7.4 Disclaimer

Content are not available

Choose License Type